Non-alcoholic fatty liver disease-related fibrosis and sarcopenia : An altered liver-muscle crosstalk leading to increased mortality risk
Copyright © 2022 Elsevier B.V. All rights reserved..
In the last few decades, the loss of skeletal muscle mass and function, known as sarcopenia, has significantly increased in prevalence, becoming a major global public health concern. On the other hand, the prevalence of non-alcoholic fatty liver disease (NAFLD) has also reached pandemic proportions, constituting the leading cause of hepatic fibrosis worldwide. Remarkably, while sarcopenia and NAFLD-related fibrosis are independently associated with all-cause mortality, the combination of both conditions entails a greater risk for all-cause and cardiac-specific mortality. Interestingly, both sarcopenia and NAFLD-related fibrosis share common pathophysiological pathways, including insulin resistance, chronic inflammation, hyperammonemia, alterations in the regulation of myokines, sex hormones and growth hormone/insulin-like growth factor-1 signaling, which may explain reciprocal connections between these two disorders. Additional contributing factors, such as the gut microbiome, may also play a role in this relationship. In skeletal muscle, phosphatidylinositol 3-kinase/Akt and myostatin signaling are the central anabolic and catabolic pathways, respectively, and the imbalance between them can lead to muscle wasting in patients with NAFLD-related fibrosis. In this review, we summarize the bidirectional influence between NAFLD-related fibrosis and sarcopenia, highlighting the main potential mechanisms involved in this complex crosstalk, and we discuss the synergistic effects of both conditions in overall and cardiovascular mortality.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:80 |
|---|---|
| Enthalten in: |
Ageing research reviews - 80(2022) vom: 15. Sept., Seite 101696 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kuchay, Mohammad Shafi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Ageing |
|---|
| Anmerkungen: |
Date Completed 16.08.2022 Date Revised 27.08.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.arr.2022.101696 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343638231 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343638231 | ||
| 003 | DE-627 | ||
| 005 | 20231226020921.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.arr.2022.101696 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1145.xml |
| 035 | |a (DE-627)NLM343638231 | ||
| 035 | |a (NLM)35843589 | ||
| 035 | |a (PII)S1568-1637(22)00138-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kuchay, Mohammad Shafi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Non-alcoholic fatty liver disease-related fibrosis and sarcopenia |b An altered liver-muscle crosstalk leading to increased mortality risk |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.08.2022 | ||
| 500 | |a Date Revised 27.08.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier B.V. All rights reserved. | ||
| 520 | |a In the last few decades, the loss of skeletal muscle mass and function, known as sarcopenia, has significantly increased in prevalence, becoming a major global public health concern. On the other hand, the prevalence of non-alcoholic fatty liver disease (NAFLD) has also reached pandemic proportions, constituting the leading cause of hepatic fibrosis worldwide. Remarkably, while sarcopenia and NAFLD-related fibrosis are independently associated with all-cause mortality, the combination of both conditions entails a greater risk for all-cause and cardiac-specific mortality. Interestingly, both sarcopenia and NAFLD-related fibrosis share common pathophysiological pathways, including insulin resistance, chronic inflammation, hyperammonemia, alterations in the regulation of myokines, sex hormones and growth hormone/insulin-like growth factor-1 signaling, which may explain reciprocal connections between these two disorders. Additional contributing factors, such as the gut microbiome, may also play a role in this relationship. In skeletal muscle, phosphatidylinositol 3-kinase/Akt and myostatin signaling are the central anabolic and catabolic pathways, respectively, and the imbalance between them can lead to muscle wasting in patients with NAFLD-related fibrosis. In this review, we summarize the bidirectional influence between NAFLD-related fibrosis and sarcopenia, highlighting the main potential mechanisms involved in this complex crosstalk, and we discuss the synergistic effects of both conditions in overall and cardiovascular mortality | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Ageing | |
| 650 | 4 | |a Liver fibrosis | |
| 650 | 4 | |a Low skeletal muscle mass | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Non-alcoholic fatty liver disease | |
| 650 | 4 | |a Sarcopenia | |
| 700 | 1 | |a Martínez-Montoro, José Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Kaur, Parjeet |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-García, José Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Ramos-Molina, Bruno |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Ageing research reviews |d 2002 |g 80(2022) vom: 15. Sept., Seite 101696 |w (DE-627)NLM119138735 |x 1872-9649 |7 nnns |
| 773 | 1 | 8 | |g volume:80 |g year:2022 |g day:15 |g month:09 |g pages:101696 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.arr.2022.101696 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 80 |j 2022 |b 15 |c 09 |h 101696 | ||